Financial Contrast: Fonar (FONR) and ENDRA Life Sciences (NDRA)

Fonar (NASDAQ:FONR) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Volatility and Risk

Fonar has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.

Earnings & Valuation

This table compares Fonar and ENDRA Life Sciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fonar $81.52 million 1.53 $21.23 million N/A N/A
ENDRA Life Sciences $10,000.00 1,014.32 -$9.80 million N/A N/A

Fonar has higher revenue and earnings than ENDRA Life Sciences.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Fonar and ENDRA Life Sciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fonar 0 0 0 0 N/A
ENDRA Life Sciences 0 0 0 0 N/A

Profitability

This table compares Fonar and ENDRA Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fonar 22.55% 18.40% 16.18%
ENDRA Life Sciences N/A -360.26% -249.53%

Institutional & Insider Ownership

51.0% of Fonar shares are owned by institutional investors. Comparatively, 18.7% of ENDRA Life Sciences shares are owned by institutional investors. 3.0% of Fonar shares are owned by insiders. Comparatively, 12.7% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Fonar beats ENDRA Life Sciences on 7 of the 9 factors compared between the two stocks.

About Fonar

FONAR Corporation, together with its subsidiaries, operates as a magnetic resonance imaging (MRI) company primarily in the Unites States. It is involved in the research, development, production, and marketing of medical scanning equipment, which uses principles of MRI for the detection and diagnosis of human diseases, abnormalities, other medical conditions, and injuries. The company operates in two segments, Manufacturing and Servicing of Medical Equipment, and Management of Diagnostic Imaging Centers. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company markets its scanners to private diagnostic imaging centers and hospitals. It also provides non-medical management services, including development, administration, office space leasing, facilities, equipment, supplies, staffing, credentialing, accounting, billing and collection, assistance with compliance matters, and practice growth and marketing strategies development and implementation services, as well as engages in the training and supervision of non-medical personnel for diagnostic imaging facilities. The company also exports its products to the United Arab Emirates, Switzerland, Canada, England, Germany, and Puerto Rico. It owns and operates 4 diagnostic imaging facilities in Florida; and manages 26 MRI scanning facilities, including 19 facilities located in New York and 7 situated in Florida. The company was founded in 1978 and is based in Melville, New York.

About ENDRA Life Sciences

ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.

Receive News & Ratings for Fonar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fonar and related companies with MarketBeat.com's FREE daily email newsletter.